Severe bronchial asthma Respiratory
Conditions
Interventions
Post hoc analysis of the OMRIA RWE study (https://doi.org/10.2147/jaa.s517194). In this analysis, the researchers used a four-component clinical-remission definition. Patients were required to meet al
ii) exacerbation-free
iii) ACT =20
and iv) no worsening from baseline in pre-bronchodilator FEV1.
The researchers checked both the medical records of the patients and the e-prescription system of the National Health System of Greece.
Sponsors
Asthma Clinics Specialist Care Practices Greece
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients =18 years of age 2. A clinical diagnosis of moderate to severe uncontrolled bronchial asthma, despite standard of care (SoC) asthma therapy (appropriate addressing of comorbidities and treatable traits, as well as adherence to GINA step 4 asthma therapy) 3. Patients were required to meet all of the following criteria at the end of the 12-month observational period in order to achieve the clinical remission definition: 3.1. Oral corticosteroid (OCS)-free 3.2. Exacerbation-free 3.3. Asthma Control Test (ACT) =20 3.4. No worsening from baseline in pre-bronchodilator FEV1 4. Have relevant medical records within the prior 12 months
Exclusion criteria
Exclusion criteria: Need for maintenance oral corticosteroids (mOCS) for causes other than asthma
Countries
Greece
Contacts
Public ContactAntonios Christopoulos
Outcome results
None listed